Avience Biomedicals IPO
Bookbuilding IPO | ₹30.00 Cr | Listing at NSE SME
IPO Open
Thu, Jun 18, 2026
IPO Close
Mon, Jun 22, 2026
Price Band
₹196.00 to ₹208.00
Market Cap (Pre-IPO)
₹114.09 Cr
IPO Details
| IPO Date | Jun 18, 2026 to Jun 22, 2026 |
| Listing Date | Tentative: Jun 25, 2026 |
| Face Value | ₹10.00 per share |
| Price Band | ₹196.00 to ₹208.00 |
| Lot Size | 600 Shares (Minimum: ₹124,800.00) |
| Sale Type | Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Issue Size | ₹30.00 Crores |
| Total Shares Offered | 1,453,800 shares |
| Fresh Issue | 1,371,600 shares |
| Offer For Sale | 1,453,800 shares |
Subscription Data
| Category | Times Subscribed |
|---|---|
| QIB | 196.77x |
| NII | 597.23x |
| Total | 385.32x |
Avience Biomedicals IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 6,83,400 |
| Retail Shares Offered | 4,81,200 |
| NII Shares Offered | 2,07,000 |
Avience Biomedicals IPO Lot Size
Investors can bid for a minimum of 1,200 shares and in multiples of 600 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 1,200 | ₹249,600 |
| Retail (Max) | 2 | 1,200 | ₹249,600 |
| S-HNI (Min) | 3 | 1,800 | ₹3,744,008 |
| S-HNI (Max) | 8 | 4,800 | ₹998,400 |
| B-HNI (Min) | 9 | 5,400 | ₹1,123,200 |
Avience Biomedicals Financial Information (Restated Consolidated)
| Period Ended | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 34.65 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| NET Worth | 28.52 | 22.78 | 6.21 |
| Reserves and Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 50.14% |
| ROCE (Return on Capital Employed) | 24.84% |
| Debt/Equity | 0.97 |
| RoNW (Return on Net Worth) | 49.89% |
| PAT Margin (Profit After Tax Margin) | 15.86% |
| EBITDA Margin | 25.22% |
| Price to Book Value | 3.68 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 17.94 | 12.56 |
| P/E (x) | 11.59 | 16.56 |
| Promoter Holding | 87.89% | 64.59% |
Company Promoters
- Mr. Dharam Deo Choudhary
- Mr. Ram Nagina Choudhary
- Mr. Janardan Pal and Ms. Deepa Choudhary.
Company Overview
Avience Biomedicals – Company Overview
- Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, export, distribution, and trading of molecular diagnostic solutions, IVD products, and medical devices.
- The company serves Pathology Labs, Microbiology Labs, Hospitals, and Research Centers across India and overseas markets.
- Its product portfolio includes Rapid Test Kits, Molecular Diagnostic Kits, Biochemistry Analyzers & Reagents, Hematology Analyzers, Oxygen Concentrators, and Viral Transport Media (VTM).
- Key products include Dengue, Malaria, and Syphilis Rapid Test Kits, COVID-19 RT-PCR Detection Kits, BS-240 Fully Auto Biochemistry Analyzer, and BC-20s Hematology Analyzer.
- The company primarily operates in the B2B and B2G segments, catering to institutional customers and government healthcare organizations.
- In addition to manufacturing, the company also acts as a distributor and trader of medical equipment.
- Its manufacturing facility is located in Noida, Uttar Pradesh.
The company focuses on biotechnology, genomics, molecular diagnostics, and in-vitro diagnostic (IVD) solutions to address diverse healthcare needs.
Company Strengths
- Strong Industry Experience and Expertise.
- Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.
- Strong distribution network across India and is growing its international footprint.
- Cost-Effective and Affordable Solutions.
- Stringent quality control processes and complies with ISO standards and regulatory approvals.
Use of Proceeds
| 1) | Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 15.96 |
| 2) | Funding the working capital requirements of the Company | 8.25 |
| 3) | General Corporate Purposes | |
| Total | 24.21 |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Quick Info
| Sector | Healthcare |
| Exchange | NSE SME |
| Market Cap (Pre-IPO) | ₹114.09 Cr |
Important Dates
| IPO Open | Jun 18, 2026 |
| IPO Close | Jun 22, 2026 |
| Allotment Date | Jun 23, 2026 |
| Credit to Demat | Jun 24, 2026 |
| Listing Date | Tentative: Jun 25, 2026 |
Lead Manager(s)
Fintellectual Corporate Advisors Pvt.Ltd.
Registrar
Skyline Financial Services Pvt.Ltd.
02228511022
Description
- IPO Type: Book build issue aggregating to ₹30.24 crores.
- Issue Structure: Entirely a fresh issue of 0.15 crore shares totaling ₹30.24 crores.
- IPO Dates: The issue opened on June 18, 2026 and closes on June 22, 2026.
- Allotment Date: The allotment is expected to be finalized on June 23, 2026.
- Listing Details: The shares are proposed to be listed on National Stock Exchange of India SME on June 25, 2026.
- Retail Investment Requirement: Minimum 2 lots (1,200 shares) amounting to approximately ₹2,49,600 (at the upper price band).
- HNI Investment Requirement: Minimum 3 lots (1,800 shares) totaling around ₹3,74,400.
- Sector: Biomedicals and healthcare products.
- Issue Price Band: ₹196 to ₹208 per equity share.
- Lot Size: 600 shares per lot.
This IPO offers investors an opportunity to participate in the biomedical and healthcare sector through a fresh issue of shares.